Publications & Presentations

May 05, 2025

Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with clinical stage GalNAc base editing medicine, VERVE-102

EAS

VERVE-102, GalNAc-LNP

2025

PCSK9

Apr 14, 2025

Initial Data from the Heart-2 Clinical Trial of VERVE-102

Other

VERVE-102, GalNAc-LNP

2025

PCSK9

Nov 16, 2024

Design of Heart-2: A Phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol

AHA

VERVE-102

2024

PCSK9

Oct 25, 2024

From Reading the Genome for Risk to Rewriting it for Cardiovascular Health

Other

VERVE-101, VERVE-102, VERVE-201, GalNAc-LNP

2024

ANGPTL3, LPA, PCSK9

Oct 22, 2024

Developing single-course gene editing medicines to treat cardiovascular disease

ESGCT

VERVE-101, VERVE-102

2024

PCSK9

Jul 07, 2024

Potent, Specific, and Durable Liver Editing of PCSK9 in Preclinical Studies of the CRISPR Base Editing Medicine VERVE-101

Other

VERVE-101

2024

PCSK9

May 17, 2024

Proof-of-concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL-Cholesterol in Humans

TIDES

VERVE-101, VERVE-102, VERVE-201

2024

ANGPTL3, LPA, PCSK9

May 11, 2024

Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off-Target Editing with the Clinical-Stage Base Editing Medicine, VERVE-101

ASGCT

VERVE-101

2024

PCSK9

Nov 13, 2023

Interim Results from the heart-1 Trial of VERVE-101 & Verve Corporate Updates

AHA

VERVE-101, VERVE-102, VERVE-201

2023

ANGPTL3, PCSK9